Wearlinq Secures $11.6M to Revolutionize Remote Cardiac Monitoring

WearLinq is thrilled to announce a major milestone in its journey to revolutionize remote cardiac monitoring, having successfully raised $11,600,000 in its latest funding round. This significant capital injection will empower the company to expand its innovative digital healthcare solutions and enhance its flagship WearLinq system, a breakthrough in ambulatory electrocardiogram (ECG) monitoring. As the first provider to introduce an FDA cleared 6-lead cardiac monitor featuring multidimensional views of the heart, WearLinq is uniquely positioned to elevate the standard of care by improving the detection of heart rhythm disorders while simultaneously reducing overall healthcare costs. With its clinical operations established in Rockville, MD and functioning as an Independent Diagnostic Testing Facility (IDTF), WearLinq continues to break new ground in the integration of cutting-edge technology and clinical practice. The new funding will be strategically allocated towards advancing product development, broadening clinical research initiatives, and accelerating regulatory approvals in new markets. By leveraging these resources, WearLinq aims to enhance its comprehensive digital platform, further refining the accuracy and reliability of remote ECG studies, which in turn will contribute significantly to early diagnosis and more effective treatment of cardiac conditions. This investment not only reflects the confidence of investors in WearLinq’s vision but also underscores the growing demand for sophisticated digital health solutions that are capable of transforming patient care. As WearLinq moves forward into this exciting phase of growth and innovation, the commitment to improving patient outcomes remains its highest priority, heralding a new era of proactive cardiovascular diagnostics and efficient healthcare management.